poisar

Stock

Cognition Therapeutics, Inc. CGTX

$0.93-4.31%

Overview

CGTX market data

Price History

CGTX price chart

Valuation & Profitability

no valuation data
No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for CGTX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

5 captured
FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug ApplicationBenzinga · Jun 24, 2026, 11:45 AM
8-K filing — COGNITION THERAPEUTICS INC (CGTX)SEC EDGAR · Jun 24, 2026, 11:39 AM
Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of ZervimesineBenzinga · Jun 16, 2026, 11:40 AM
Cognition Therapeutics Discloses May 20 Meeting With FDA To Review Results From Its Phase 2 Study Of Zervimesine And Discuss Design And Endpoints Of A Study In Dementia With Lewy Bodies Patients With PsychosisBenzinga · May 21, 2026, 11:45 AM
Cognition Therapeutics Announces Second Philanthropic Donation From A Participant In The Ongoing Expanded Access Program For People With Dementia With Lewy BodiesBenzinga · May 14, 2026, 11:34 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock